Boehringer Ingelheim and Circuit Therapeutics have entered into a research collaboration for the discovery of new ways of treating psychiatric disorders. Circuit Therapeutics’ flagship technology, optogenetics platform allows the identification and characterization of drug targets from brain circuits involved in normal and pathological behaviors and allows the control of individual nerve cells and circuits. The companies will combine R&D capabilities to provide novel avenues for drug discovery in a three-year research program. Further details were not disclosed.
"We are excited to work with Boehringer Ingelheim to utilize Circuit's unique capabilities to advance drug discovery. The innovative and ambitious vision and passion of Boehringer Ingelheim to make a difference in the area of neuropsychiatric disease treatments combined with Circuit's innovative technologies makes an ideal partnership. We look forward to a highly productive research collaboration that will provide transformational drugs to impact patients' lives," said Fred Moll, chairman of Circuit Therapeutics.
Circuit, Boehringer in Psychiatric Drug Discovery Pact
By Kristin Brooks
Published December 19, 2013
blog comments powered by Disqus